Uncertain, Not Unfinished: Reading a VUS on a 2026 NHS Genomic Report

A genomic report lands in the clinic folder. Somewhere in the middle is a line that says 'variant of uncertain significance'. It is not the sentence anyone wanted, and it is not the sentence many people hear. In a busy appointment, VUS can morph into 'there’s a fault in a gene' or 'we found something, but we’re not sure yet'. Both versions are understandable. Neither is quite what the report says.

So let’s do a plain-English audit of a typical NHS Genomic Medicine Service report in 2026. Not a real patient, not a real family, just the sort of layout and language that turns up in UK clinical genetics. The aim is simple: read the VUS as a scientific statement about evidence, not as a verdict about a person.

First, find what the report is not saying

A VUS sits in the middle of a five-tier classification system. At one end: pathogenic. At the other: benign. A VUS is not a soft diagnosis, a pre-diagnosis or a 'probably'. It means the lab has seen a DNA change, checked it against the evidence available, and decided the evidence is not strong enough to call it disease-causing or harmless.

That distinction matters because NHS reports are built to be acted on. A pathogenic or likely pathogenic result usually connects to a clinical pathway: screening, family testing, a treatment decision, a referral. A VUS usually does not. It is a placeholder for 'revisit when the evidence changes'.

The fields that change the sentence

Read the VUS line with four other bits of the report nearby.

Gene and transcript. A variant is described against a specific transcript, not just a gene name. Different transcripts can produce different HGVS descriptions. If you are comparing letters, make sure you are comparing the same transcript and genome build. This is the genomic equivalent of checking you are looking at the right version of a document.

Zygosity. Is the variant heterozygous, homozygous or hemizygous? That tells you whether one copy or both copies carry the change, and it shapes how inheritance is discussed. It does not, by itself, tell you whether the change matters.

Inheritance pattern. The report may note that the gene is associated with autosomal dominant, autosomal recessive, X-linked or mitochondrial inheritance. That is background about the gene, not a prediction about the family. A VUS in a dominant gene does not automatically mean a 50% risk to children. It means the gene’s inheritance pattern is one part of the evidence picture.

Actionability. Look for an interpretation or comments section. Does the report say the variant is in a clinically actionable gene? Does it mention specific management recommendations? For a VUS, the honest answer is often 'no change to management based on this variant alone'. That is not a brush-off. It is the clinical boundary of what the evidence supports.

Inheritance is a family question, not a fortune-telling exercise

In a UK clinic, a VUS often triggers a conversation about family testing. Sometimes relatives can be tested for the same variant to see whether it tracks with a condition in the family. Sometimes that is not useful because the evidence is too thin. The report should give enough detail for a clinical genetics team to make that call.

What a VUS should not do is generate a round of untargeted testing in relatives just because the word 'variant' sounds serious. If a family member is offered testing, ask what the result would change. If the answer is 'nothing this year', that is worth knowing before anyone books a blood test.

Actionability in 2026: what can actually be done now?

This is the question that separates a report from a plan. For many VUS results, the answer is active surveillance of the evidence, not active treatment. In 2026, that means asking three things.

First, is there a published evidence review date in the report or trust letter? Second, does the laboratory have a reanalysis policy? Third, is there a named route for the clinical team to request reanalysis if new evidence appears?

Reanalysis timelines vary across the UK. Some services review VUS results at set intervals; others rely on a clinician or patient prompting a review when a new paper, database update or family history emerges. There is no single national clock printed on every report. That is exactly why the question is worth asking.

A sensible prompt is usually two to three years after the original result, or sooner if something material changes: a new publication, a new family diagnosis, a treatment licence, or an updated guidance document. The point is not to chase the lab monthly. The point is to make sure 'uncertain' has a review route attached to it.

Questions to take into the appointment

• Which gene, transcript and genome build is this variant reported against?
• Is the classification a VUS because evidence is limited, conflicting or simply absent?
• Does this variant change any screening, treatment or family-testing recommendation today?
• If not, what would need to change for it to become actionable?
• Does the laboratory have a reanalysis pathway, and who triggers it?
• Is there a copy of the report in the patient portal or letter that includes the interpretation section, not just the summary?

Those questions are not adversarial. They are the difference between a report that sits in a folder and a report that sits inside a plan.

The bottom line

A VUS is not a verdict. It is a temporary scientific position, written in a report that has to serve a clinical purpose. In 2026, the useful reading is neither 'everything is fine' nor 'something is wrong'. It is: here is what the evidence currently supports, here is what it does not, and here is when we should look again.

If you are holding a report with a VUS, ask for the interpretation section, ask what it does not change, and ask who owns the next review. That is not asking for certainty. It is asking for a process.